ADMA Biologics Inc. (ADMA)

ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY r...

ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025.

ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossm...

Adma Biologics (ADMA) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.08 per share a year ago.

While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotec...

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Adma Biologics (ADMA) concluded the recent trading session at $23.52, signifying a +1.07% move from its prior day's close.

Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.

Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.

Zacks.com users have recently been watching Adma Biologics (ADMA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.